What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now.
What revenues will cancer treatment markets generate from 2011 to 2021? What gains will leading companies and products achieve? What sales trends will leading national markets - developed and developing - show?
Our study answers those questions and many others for anti-cancer agents. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.
Anti-cancer drug sales exceeded $50bn worldwide in 2009, with impressive growth. Our report shows you where cancer therapies are heading from 2011 to 2021 - technology, competition and revenues.
Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). We show the potential for cancer treatments, existing and in development.
Our report shows you revenue forecasts at total world, sub-market, product and national levels. You can assess the potential of the anti-cancer drug industry and market now.
We show the industry's strengths, weaknesses, trends and opportunities from 2011. We show you oncology R&D trends - pipeline and emerging treatments to look out for.
In our report you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.
Analysis and expert opinion to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 149 tables and charts and a research interview (shown in the accompanying lists).
Delaying ordering could mean you miss out on data, opinion and trends that your competitors use to positively influence their business decisions.
Leading Anti-Cancer Drugs: World Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
• You will receive analysis of leading anti-cancer drugs from 2009 to 2021, including predicted revenues, market shares and growth rates
• You will find revenue predictions for Avastin, MabThera, Herceptin, Glivec, Taxotere, Arimidex, Erbitux, Alimta, Revlimid and Velcade
• You will receive a forecast for the overall world cancer drugs market from 2011 to 2021
• You will receive forecasts for the main drug categories at world level - traditional antineoplastics, novel antineoplastics, hormone therapies and immunotherapies
• You will receive sales forecasts for the leading national markets from 2011 to 2021 (US, Japan, France, Germany, Italy, Spain, UK, China, Russia, India and Brazil)
• You will assess leading companies' activities and prospects in the anti-cancer drug market
• You will investigate competition and opportunities that will influence the cancer treatments industry and market from 2011 onwards
• You will see what will stimulate and restrain the industry and market
• You will review product development, assessing the potential of oncology R&D and emerging products for lung, breast, colorectal, stomach and prostate cancers
• You will investigate commercial requirements - with therapeutic needs and market opportunities discussed
• You will see discussions of personalised medicine and biosimilar drugs in cancer treatment
• You will view expert opinion from our survey, including a full interview transcript.
That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - predictions found only in our work. Our independent analysis helps you stay ahead in market knowledge.
You can order our report, receiving the market information you need
Our report can benefit everybody interested in cancer drug development, production, marketing and sales. We give predictions and answers you need. Please order our report now, making sure you don't miss out.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Global Drug And Medication Industry
Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research Methods
1.4 Scope of this Report
1.4.1 Drug Types Excluded from this Report
1.5 Abbreviations Used in this Report
2. Introduction: Cancer, its Physiology, Burden and Treatment
2.1 The Physiology of Cancer
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival
2.2.3.1 The Developed World
2.2.3.2 The Developing World
2.3 Treating Tumours
2.3.1 Chemotherapy
2.3.2 Traditional Antineoplastics
2.3.3 Novel Antineoplastics
2.3.3.1 Kinase Receptor Antagonists
2.3.3.2 Other Novel Antineoplastics
2.3.4 Hormone Therapies
2.3.5 Active Immunotherapy
2.3.6 Passive Immunotherapy: Monoclonal Antibodies
3. The Global Cancer Drugs Market 2011-2021
3.1 Global Cancer Drugs Market 2009
3.2 Global Cancer Drugs Market Forecast 2011-2021
3.3 Traditional Antineoplastics Market Forecast 2011-2021
3.4 Novel Antineoplastics Market Forecast 2011-2021
3.5 Hormone Therapy Market Forecast 2011-2021
3.6 Immunotherapy Market Forecast 2011-2021
4. Cancer Drugs: Leading National Market Forecasts 2011-2021
4.1 National Cancer Drug Markets 2009
4.2 The US
4.3 Japan
4.4 The EU Top Five
4.5 BRIC Countries
4.5.1 Brazil
4.5.2 Russia
4.5.3 India
4.5.4 China
5. Top 10 Cancer Drugs: Sales Forecasts 2011-2021
5.1 Market Dominated by Monoclonal Antibodies
5.2 Avastin
5.2.1 Avastin Sales 2009
5.2.2 Recent Developments
5.2.3 Avastin Sales Forecast 2011-2021
5.3 MabThera
5.3.1 MabThera Sales 2009
5.3.2 Recent Developments
5.3.3 Sales Forecast 2011-2021
5.3.4 Increased Competition
5.3.5 Biosimilar MabThera
5.4 Herceptin
5.4.1 Herceptin Sales 2009
5.4.2 Recent Developments
5.4.3 Herceptin Sales Forecast 2011-2021
5.5 Glivec
5.5.1 Glivec Sales 2009
5.5.2 Glivec Sales Forecast 2011-2021
5.5.3 Tasigna Set to Replace Glivec
5.6 Taxotere
5.6.1 Taxotere Sales 2009
5.6.2 Patent Expiry
5.6.3 Taxotere Sales Forecast 2011-2021
5.7 Arimidex
5.7.1 Arimidex Sales 2009
5.7.2 Patent Expiry
5.8 Erbitux
5.8.1 Erbitux Sales 2009
5.8.2 Recent Developments
5.8.3 Erbitux Sales Forecast 2011-2021
5.9 Alimta
5.9.1 Alimta Sales 2009
5.9.2 Patent Disputes
5.9.3 Alimta Sales Forecast 2011-2021
5.10 Revlimid
5.10.1 Revlimid Sales 2009
5.10.2 Secondary Malignancies
5.10.3 Revlimid Sales Forecast 2011-2021
5.11 Velcade
5.11.1 Velcade Sales 2009
5.11.2 Recent Developments
5.11.3 Velcade Sales Forecast 2011-2021
6. Leading Companies in Cancer Drugs 2010
6.1 A Marketed Dominated by a Few Companies
6.2 Roche
6.2.1 Market Leader in 2009
6.2.2 Financial Performance 2010
6.2.3 Oncology Pipeline
6.2.4 Future Directions in Cancer
6.3 Novartis
6.3.1 Leading Cancer Drugs 2009
6.3.2 Financial Performance 2010
6.3.3 Oncology Pipeline
6.3.4 Future Directions in Cancer
6.4 AstraZeneca
6.4.1 Leading Cancer Drugs 2009
6.4.2 Financial Performance 2010
6.4.3 Oncology Pipeline
6.4.4 Future Directions in Cancer
6.5 Sanofi-Aventis
6.5.1 Leading Cancer Drugs 2009
6.5.2 Financial Performance 2010
6.5.3 Oncology Pipeline
6.5.4 Future Directions in Cancer
6.6 Eli Lilly
6.6.1 Leading Cancer Drugs 2009
6.6.2 Patent Issues 2010
6.6.3 Oncology Pipeline
6.6.4 Future Directions in Cancer
7. Pipeline Trends in Cancer 2011-2021
7.1 Immunotherapy: The Future of Cancer Treatment
7.1.1 Passive Immunotherapy
7.1.2 Active Immunotherapy
7.2 Lung Cancer Pipeline 2010
7.2.1 Line Extensions
7.2.2 BIBW 2992
7.2.3 MAGE-A3 ASCI
7.2.4 Talactoferrin
7.3 Breast Cancer Pipeline 2010
7.3.1 Line Extensions
7.3.2 Halaven
7.4 Colorectal Cancer Pipeline 2010
7.4.1 BAY 73-4506
7.4.2 KRX 0401
7.5 Stomach Cancer Pipeline 2010
7.5.1 Line Extensions
7.5.2 IMC1121B
7.6 Prostate Cancer Pipeline 2010
7.6.1 Provenge
7.6.2 MDV 3100
7.6.3 CB7630
7.6.4 Custirsen
8. SWOT Analysis for Cancer Drugs 2011-2021
8.1 SWOT Chart for the World Cancer Drugs Market 2011-2021
8.2 Strengths
8.2.1 High Profile Nature of Cancer
8.2.2 Off-Label Prescriptions are Common
8.2.3 Strong Drug Development Incentives
8.3 Weaknesses
8.3.1 Tumour Resistance
8.3.2 Pricing-Out the Developing World
8.4 Opportunities
8.4.1 Rising Incidence of Cancer
8.4.1.1 Aging Populations
8.4.1.2 Smoking
8.4.1.3 Obesity
8.4.1.4 The Developing World
8.4.2 Personalised Medicine
8.4.3 Live Licensing
8.4.4 Convenient Drugs
8.5 Threats
8.5.1 The Cost-Effectiveness Debate
8.5.2 Governments are a Leading Payer for Drugs
8.5.3 Efficacy, Toxicity and Alternative Treatments
8.6 Biosimilars and Generics: Opportunity or Threat?
8.7 Personalised Medicine
8.7.1 Cancer Heterogeneity
8.7.2 Pharmacogenomics
8.7.3 Genome Screening
8.7.4 Biomarkers and Diagnostics
8.7.5 Theranostics
9. Expert Opinion
9.1 Dr Janice M. Reichert
9.1.1 Main Challenges of Monoclonal Antibodies as Cancer Therapy
9.1.2 Main Opportunities
9.1.3 Side Effects of Monoclonal Antibodies
9.1.4 Future Developments and Pipelines
9.1.5 The Effect of Biosimilars
10. Conclusions
10.1 The US Will Continue to be the World's Largest Cancer Drug Market
10.2 India and China Will be the Fastest Growing National Markets
10.3 Monoclonal Antibodies Will Dominate the Market
10.3.1 Biosimilars Have Potential in Emerging Markets
10.4 Personalised Medicine Will Become More Commonplace
10.5 Pipelines for Many Cancer Types Are Strong
10.6 Concluding Remarks
List of Tables
Table 1.1 Abbreviations Used in the Report
Table 2.1 Leading Causes of Death Worldwide, 2008-2015
Table 2.2 Ten Most Common Cancers by Incidence, 2008
Table 2.3 Ten Most Common Cancers by Mortality, 2008 & 2015
Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Table 2.5 Categories of Oncology Drug, 2010
Table 2.6 Common Side-Effects of Traditional Antineoplastic Chemotherapy
Table 2.7 Subcategories of TANs
Table 3.1 Global Cancer Drugs Market by Category, 2009
Table 3.2 Cancer Immunotherapy Sales, 2009
Table 3.3 Traditional Antineoplastics Sales, 2009
Table 3.4 Global Cancer Drugs Market Forecast, 2009-2021
Table 3.5 Global Cancer Drugs Market Drivers and Restraints, 2011-2021
Table 3.6 Traditional Antineoplastics Market Forecast, 2009-2021
Table 3.7 Novel Antineoplastics Market Forecast, 2009-2021
Table 3.8 Novel Antineoplastics Drivers & Restraints, 2011-2021
Table 3.9 Hormone Therapy Market Forecast, 2009-2021
Table 3.10 Hormone Therapy Drivers & Restraints, 2011-2021
Table 3.11 Immunotherapy Drivers & Restraints, 2011-2021
Table 3.12 Immunotherapy Market Forecast, 2009-2021
Table 4.1 Global Cancer Drugs Market by Region, 2009
Table 4.2 Developed Markets Drivers and Restraints, 2011-2021
Table 4.3 Emerging Markets Drivers and Restraints, 2011-2021
Table 4.4 Global Cancer Drugs Market Forecast by Region, 2009-2021
Table 5.1 Top Ten Cancer Drugs Sales, 2009
Table 5.2 Top Ten Cancer Drugs: Key Facts, 2009
Table 5.3 Potential New Indications for Avastin, January 2010
Table 5.4 Avastin Sales Drivers and Restraints, 2011-2021
Table 5.5 Avastin Sales Forecast, 2009-2021
Table 5.6 MabThera Sales Forecast, 2009-2021
Table 5.7 MabThera Sales Drivers and Restraints, 2011-2021
Table 5.8 Herceptin Sales, 2007-2009
Table 5.9 Herceptin Sales Forecast, 2009-2021
Table 5.10 Herceptin Sales Drivers and Restraints, 2011-2021
Table 5.11 Glivec Sales by Region, 2009
Table 5.12 Glivec Sales Forecast, 2009-2021
Table 5.13 Glivec Sales Drivers and Restraints, 2011-2021
Table 5.14 Taxotere Approved Indications, 2010
Table 5.15 Taxotere Sales by Region, 2009
Table 5.16 Taxotere Sales Forecast, 2009-2021
Table 5.17 Taxotere Sales Drivers and Restraints, 2011-2021
Table 5.18 Arimidex Sales by Region, 2009
Table 5.19 Arimidex Sales by Region, Q1-Q3 2010
Table 5.20 Arimidex Sales Forecast, 2009-2021
Table 5.21 Arimidex Sales Drivers and Restraints, 2011-2021
Table 5.22 Erbitux Sales by Company, 2009
Table 5.23 Erbitux Sales Drivers and Restraints, 2011-2021
Table 5.24 Erbitux Sales Forecast, 2009-2021
Table 5.25 Alimta Sales by Region, 2009
Table 5.26 Alimta Sales Forecast, 2009-2021
Table 5.27 Alimta Sales Drivers and Restraints, 2011-2021
Table 5.28 Revlimid Sales Forecast, 2009-2021
Table 5.29 Revlimid Sales Drivers and Restraints, 2011-2021
Table 5.30 Velcade Sales by Company, 2009
Table 5.31 Velcade Sales Forecast, 2009-2021
Table 5.32 Velcade Sales Drivers and Restraints, 2011-2021
Table 6.1 Cancer Drugs Market by Company, 2009
Table 6.2 Roche Sales by Sector, 2009
Table 6.3 Roche Oncology Sales, 2009
Table 6.4 Roche Oncology Sales, H1 2010
Table 6.5 Roche Oncology Pipeline, November 2010
Table 6.6 Novartis Sales by Sector, 2009
Table 6.7 Novartis Oncology Sales, 2009
Table 6.8 Novartis Oncology Sales, Q1-Q3 2010
Table 6.9 Novartis Oncology Pipeline, 2010
Table 6.10 AstraZeneca Sales by Sector, 2009
Table 6.11 AstraZeneca Oncology Sales, 2009
Table 6.12 AstraZeneca Oncology Sales, Q1-Q3 2010
Table 6.13 AstraZeneca Oncology Pipeline, July 2010
Table 6.14 Sanofi-Aventis Sales by Sector, 2009
Table 6.15 Sanofi-Aventis Oncology Sales by Region, 2009
Table 6.16 Sanofi-Aventis Oncology Sales, H1 2010
Table 6.17 Sanofi-Aventis Oncology Pipeline, February 2010
Table 6.18 Eli Lilly Sales by Sector, 2009
Table 6.19 Eli Lilly Oncology Sales, 2009
Table 6.20 Eli Lilly Oncology Pipeline, 2010
Table 7.1 Number of Drug Candidates by Indication, 2009
Table 7.2 Abbreviations Used in Chapter 7
Table 7.3 Therapeutic Cancer Vaccines in Phase III, 2010
Table 7.4 Selected Lung Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.5 Selected Breast Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.6 Selected Colorectal Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.7 Selected Stomach Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.8 Selected Prostate Cancer Pipeline Candidates in Phase II & III, 2010
Table 8.1 SWOT Chart for the World Cancer Drugs Market, 2011-2021
Table 10.1 Global Cancer Drugs Market by Region, 2009-2021
Table 10.2 Global Cancer Drugs Market by Drug Type, 2009-2021
List of Figures
Figure 2.1 Leading Causes of Death Worldwide, 2008-2015
Figure 2.2 Ten Most Common Cancers by Incidence, 2008
Figure 2.3 Ten Most Common Cancers by Mortality, 2008
Figure 2.4 Ten Most Common Cancers by Mortality, 2015
Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Figure 3.1 Global Cancer Drugs Market by Category, 2009
Figure 3.2 Cancer Immunotherapy Sales, 2009
Figure 3.3 Traditional Antineoplastics Sales, 2009
Figure 3.4 Global Cancer Drugs Market Forecast, 2009-2021
Figure 3.5 Traditional Antineoplastics Market Forecast, 2009-2021
Figure 3.6 Novel Antineoplastics Market Forecast, 2009-2021
Figure 3.7 Hormone Therapy Market Forecast, 2009-2021
Figure 3.8 Immunotherapy Market Forecast, 2009-2021
Figure 4.1 Global Cancer Drugs Market by Region, 2009
Figure 4.2 Global Cancer Drugs Market by Region, 2015
Figure 4.3 Global Cancer Drugs Market by Region, 2021
Figure 4.4 US Cancer Drugs Market Forecast, 2009-2021
Figure 4.5 Japanese Cancer Drugs Market Forecast, 2009-2021
Figure 4.6 Top Five European Cancer Drugs Market Forecasts, 2009-2021
Figure 4.7 Brazilian Cancer Drugs Market Forecast, 2009-2021
Figure 4.8 Russian Cancer Drugs Market Forecast, 2009-2021
Figure 4.9 Indian Cancer Drugs Market Forecast, 2009-2021
Figure 4.10 BRIC National Cancer Drugs Markets, 2009
Figure 4.11 Chinese Cancer Drugs Market Forecast, 2009-2021
Figure 5.1 Top Ten Cancer Drugs Sales, 2009
Figure 5.2 Top Ten Cancer Drugs Sales by Drug Category, 2009
Figure 5.3 Avastin Sales Forecast, 2009-2021
Figure 5.4 MabThera Sales Forecast, 2009-2021
Figure 5.5 Herceptin Sales, 2007-2009
Figure 5.6 Herceptin Sales Forecast, 2009-2021
Figure 5.7 Glivec Sales by Region, 2009
Figure 5.8 Glivec Sales Forecast, 2009-2021
Figure 5.9 Taxotere Sales by Region, 2009
Figure 5.10 Taxotere Sales Forecast, 2009-2021
Figure 5.11 Arimidex Sales by Region, 2009
Figure 5.12 Arimidex Sales by Region, Q1-Q3 2010
Figure 5.13 Arimidex Sales Forecast, 2009-2021
Figure 5.14 Erbitux Sales by Company, 2009
Figure 5.15 Erbitux Sales Forecast, 2009-2021
Figure 5.16 Alimta Sales by Region, 2009
Figure 5.17 Alimta Sales Forecast, 2009-2021
Figure 5.18 Revlimid Sales Forecast, 2009-2021
Figure 5.19 Velcade Sales by Company, 2009
Figure 5.20 Velcade Sales Forecast, 2009-2021
Figure 6.1 Cancer Drugs Market by Company, 2009
Figure 6.2 Roche Sales by Sector, 2009
Figure 6.3 Roche Oncology Sales, 2009
Figure 6.4 Roche Oncology Sales, H1 2010
Figure 6.5 Novartis Sales by Sector, 2009
Figure 6.6 Novartis Oncology Sales, 2009
Figure 6.7 Novartis Oncology Sales, Q1-Q3 2010
Figure 6.8 AstraZeneca Sales by Sector, 2009
Figure 6.9 AstraZeneca Oncology Sales, 2009
Figure 6.10 AstraZeneca Oncology Sales, Q1-Q3 2010
Figure 6.11 Sanofi-Aventis Sales by Sector, 2009
Figure 6.12 Sanofi-Aventis Oncology Sales, 2009
Figure 6.13 Sanofi-Aventis Oncology Sales by Region, 2009
Figure 6.14 Sanofi-Aventis Oncology Sales, H1 2010
Figure 6.15 Eli Lilly Sales by Sector, 2009
Figure 6.16 Eli Lilly Oncology Sales, 2009
Figure 7.1 Number of Drug Candidates by Indication, 2009
Figure 7.2 Therapeutic Cancer Vaccines in Phase III, 2010
Companies Listed
AB Science
Abbott Laboratories
Abraxis BioScience
Actavis
Active Biotech
Agennix
Allos Therapeutics
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Amgen
Apotex
APP Pharmaceuticals
ARIAD Pharmaceuticals
Ascenta Therapeutics
Astellas Pharma
AstraZeneca
Æterna Zentaris
Attenuon
Barr Laboratories
Bayer
Biogen Idec
Bionovo
BiPar Sciences
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Research Technology
Cancer Research UK
Celgene
Centocor Ortho Biotech
Cipla
Concordia Pharmaceuticals
Cougar Biotechnology
CureVac
CuraGen
Cyclacel Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Dako
Dendreon
Dr. Reddy's Laboratories
Eisai
Eleison Pharmaceuticals
Eli Lilly
EMA
Endocyte
EntreMed
Exelixis
FDA
Fresenius Kabi
Genentech
Generex Biotechnology
Genmab
Genta
Genzyme
GlaxoSmithKline
GPC Biotech
Hospira
ImClone Systems
ImmunoGen
Incyte
Infinity Pharmaceuticals
Intas Biopharmaceuticals
International Cancer Genome Consortium
Introgen Therapeutics
Isis Pharmaceuticals
Johnson & Johnson
Janssen
Keryx Biopharmaceuticals
Lonza
Marshall Edwards
Medivation
Merck KGaA
Merck Serono
Micromet
Millennium Pharmaceuticals
Mylan
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Clinical Excellence (NICE) [UK]
Nektar Therapeutics
Novartis
Novogen
OncoGenex Pharmaceuticals
Ono Pharmaceuticals
Onyx Pharmaceuticals
Oxford University
Par Pharmaceutical
Pfizer
Pharmaceutical Researchers and Manufacturers of America (PhRMA) [US]
PharmaMar USA
Pierre Fabre Pharmaceuticals
Poniard Pharmaceuticals
Princeton University
Proacta
Proteolix
Radient Pharmaceuticals
Regeneron
Roche
Roxane Laboratories
Sandoz
Sanofi-Aventis
Scancell
Schering-Plough
Spectrum Pharmaceuticals
Stada Arzneimittel
Sun Pharmaceuticals
Syndax Pharmaceuticals
Taiho Pharma USA
Takeda
Tapestry Pharmaceuticals
TargeGen
Teva Pharmaceutical Industries
Threshold Pharmaceuticals
TopoTarget
Tufts University
World Health Organisation (WHO)
WILEX
Yeda Research and Development Company
Zenyaku Kogyo
